Capturing the value of environmental impact and sustainability in pharmaceutical health technology assessment

The healthcare sector is responsible for a substantial share of global carbon emissions, contributing approximately 4-5% of total global greenhouse gas emissions.
Read now
HTA outcome for ATMPs in the three Scandinavian countries Sweden, Norway, Denmark
What is the outcome of ATMPs that has been approved by the EMA in the Scandinavian markets?
Valtermed: The Spanish National Health System’s information system that collects real world evidence on the therapeutic value of new therapeutics
In recent years, new pharmaceutical policies have been implemented in the Spanish National Health System (NHS) aiming to restrain pharmaceutical spending and improve transparency in healthcare decision making. Among them, there has been an increase in the use of performance-based agreements at national and regional level, as well as the development of the Valtermed program.
New Horizonscan reveals upcoming pharmaceutical advances   
Zorginstituut Nederland (ZIN) has released the latest Horizonscan, outlining the expected introduction of 246 new medicines and 189 existing medicines for new indications in the European market over the next two years.
New AIFA regulation: where are we?
Almost one year after the publication of the relevant law, the long-awaited reorganisation of the Italian Medicines Agency (AIFA) seems to be close to its final approval and implementation.